In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells
When Sernova announced in June that five patients with type 1 diabetes with severe hyperglycemia and a complete inability to produce insulin were able to come off of insulin after receiving its cell transplant therapy, it was the latest example of promising science in the type 1 category.
Sernova’s treatment takes islets — the pancreatic cell group that includes beta cells, which are responsible for making insulin — from a donor and delivers them via what the biotech calls a “cell pouch,” a porous and flexible device about the size of a credit card that is loaded with islet cells and implanted under the skin against the abdomen.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
